Market Performance - The Sci-Tech Innovation Board (STAR Market) index rose by 0.23%, closing at 1390.39 points, with a total trading volume of 3.856 billion shares and a turnover of 177.074 billion yuan, resulting in an average turnover rate of 2.02% [1] - Among the tradable stocks on the STAR Market, 256 stocks closed higher, with 4 stocks rising over 10%, including Arctech and Jinkuang Electric, while 327 stocks closed lower, with 1 stock declining over 10% [1] Stock Turnover Rates - The distribution of turnover rates shows that 2 stocks had turnover rates exceeding 20%, 11 stocks had rates between 10% and 20%, and 41 stocks had rates between 5% and 10% [1] - The stock with the highest turnover rate was He Yuan Biological, which closed down by 12.55% with a turnover rate of 45.34% and a transaction amount of 2.206 billion yuan [1] Sector Analysis - In terms of sector performance, the electronics sector had the most stocks with a turnover rate exceeding 5%, totaling 18 stocks, followed by the power equipment and pharmaceutical sectors with 17 and 6 stocks, respectively [2] - The stocks with the highest net inflow of funds included Arctech, Trina Solar, and Jinkuang Technology, with net inflows of 406 million yuan, 331 million yuan, and 175 million yuan, respectively [2] Leverage Fund Movements - A total of 36 stocks with high turnover rates recently received net purchases from leveraged funds, with the largest increases in financing balances seen in Guo Dun Quantum, Arctech, and Jinkuang Technology, which increased by 350 million yuan, 293 million yuan, and 185 million yuan, respectively [2] Notable Stocks - The top stocks by turnover rate on November 5 included He Yuan Biological, which fell by 12.55% with a turnover rate of 45.34%, and Arctech, which rose by 20.02% with a turnover rate of 15.46% [3][4] - Other notable stocks included Jinkuang Electric, which increased by 19.99%, and Jinkuang Technology, which rose by 18.12% [2][3]

Report Industry Investment Rating No relevant content provided. Core Views of the Report - In October 2025, the restart of unprofitable new shares issuance led to an increase in the monthly fundraising amount, and the new shares on the first - day of listing had no break - even, with an average increase of 219%. The new share subscription income remained high, and the "entry" strategy was the optimal one [2]. - The performance of new shares in different sectors and industries varies. The first - day performance of unprofitable new shares on the Science and Technology Innovation Board was excellent, and the choice of restricted - sale plans for unprofitable new shares had a significant impact on income enhancement [11][17]. Summary by Related Catalogs 1. Issuance and Listing Rhythm - In October 2025, there were 9 new listings on the Shanghai, Shenzhen, and Beijing stock exchanges, with a total initial public offering (IPO) fundraising of 1.2869 billion yuan. From January to October 2025, there were 87 new listings, and the total fundraising was 9.0172 billion yuan, a 9% increase in the number of new listings and a 71% increase in fundraising compared to the same period in 2024 [2][8]. - The 3 unprofitable new shares listed in October 2025 had a relatively large fundraising volume, driving the monthly fundraising amount to increase year - on - year and month - on - month [2][8]. 2. First - day Gain Performance - In October 2025, the 6 new shares listed in the Shanghai and Shenzhen markets were all issued offline. The new shares on the first - day of listing had no break - even, with an average increase of 219%, the same as in September. The average first - day increase of the first 3 unprofitable new shares on the Science and Technology Innovation Board with agreed restricted sales was 158% [2][11]. - Among the new shares on the Main Board in October, Daosheng Tianhe had a first - day increase of 351%, Chaoying Electronics had a first - day increase of 339%, and Marco Polo had a first - day increase of 148% [11]. 3. New Share Subscription Income Calculation - In October 2025, with the support of unprofitable new share income, the monthly new share subscription income remained high. Without considering unprofitable new shares, the new share subscription income of Class A/B accounts in October was 287,700/277,200 yuan respectively. Conservatively, if all 3 unprofitable new shares selected Plan A3, the total monthly full - subscription income of Class A/B was 623,400/608,800 yuan; optimistically, if all 3 unprofitable new shares selected Plan A1, the total monthly full - subscription income of Class A/B was 3,971,500/608,800 yuan [2][17]. 4. New Share Subscription Strategy at the Current Stage - The "entry" strategy is still the optimal one. It is recommended to actively participate in low - price, small - floating - stock new shares with expected first - day gains and large - market - value new shares with a large offline allocation volume. Among the registered but unlisted enterprises, companies such as Moore Threads are worth paying attention to [2][20]. - The performance of new shares in different sectors is affected by various factors. The Main Board new shares have had good performance and high first - day gains since 2023; the Science and Technology Innovation Board new shares are affected by market heat and policy support; the ChiNext Board is recommended to participate in low - price, small - market - value new shares [20].

Group 1 - The core viewpoint of the article highlights a collective decline in the A-share market for innovative drug concept stocks, with significant drops in several companies [1] Group 2 - Changshan Pharmaceutical experienced a decline of over 19%, with a total market capitalization of 51.7 billion and a year-to-date increase of 181.54% [2] - Zicheng Pharmaceutical and Baiyang Pharmaceutical both fell by over 7%, with market capitalizations of 6.984 billion and 13.3 billion respectively, and year-to-date increases of 68.53% and 9.05% [2] - Other companies such as Bibete-U, Kangchen Pharmaceutical, and Kanghong Pharmaceutical saw declines exceeding 5%, with market capitalizations of 14.3 billion, 28.8 billion, and respective year-to-date increases of 79.30% and 62.53% [2] - The article also notes that MACD golden cross signals have formed, indicating potential upward momentum for some stocks [1]

- The report tracks the recent IPO performance in the A-share market, including the Sci-Tech Innovation Board, ChiNext, and Main Board, assuming all stocks are successfully subscribed and sold at the market average price on the first trading day, ignoring lock-up restrictions[2][10][39] - For A-class accounts with a scale of 2 billion, the IPO yield since the beginning of 2025 until October 31, 2025, is 2.65%, while for B-class accounts of the same scale, the yield is 2.23%[2][10][39] - For larger accounts with a scale of 10 billion, the IPO yield for A-class accounts is 0.96%, and for B-class accounts, it is 0.73%[2][10][39] - The average first-day increase for Sci-Tech Innovation Board stocks is 219.94%, while for ChiNext stocks, it is 244.28%[2][18][39] - The report calculates the theoretical IPO yield using the formula: $ Class Full Subscription Quantity = Maximum Subscription Limit × Average Class Offline Winning Rate $ $ Full Subscription Yield = (First Opening Price - Initial Offering Price) × Full Subscription Quantity $[38][39][41] - The full subscription yield for individual stocks mostly ranges between 5 to 100 thousand yuan, with the highest yields being C奕材-U (98.18 thousand yuan), C禾元-U (78.03 thousand yuan), and 联合动力 (50.81 thousand yuan)[38][39][41] - The report provides detailed monthly IPO yield calculations for different account scales (1.5 billion, 2 billion, 3 billion, 5 billion, and 10 billion) across Sci-Tech Innovation Board, ChiNext, and Main Board, assuming 90% capital utilization efficiency and all quotes successfully included[39][42][46]

Core Points - The listing of three unprofitable high-tech companies on the Sci-Tech Innovation Board marks a significant step in capital market support for technological innovation and new productivity development [2][4] - The establishment of the Sci-Tech Growth Layer enhances market inclusivity and strengthens the capital market's role in serving the real economy [1][10] Group 1: New Listings - Three companies, Bibet (688759.SH), Heyuan Bio (688765.SH), and Xi'an Yicai (688783.SH), were listed on the Sci-Tech Innovation Board, representing the first batch of new registered enterprises in the Sci-Tech Growth Layer [1][2] - Bibet focuses on innovative drug development, with its product BEBT-908 approved for treating various blood cancers and solid tumors [2][3] - Heyuan Bio has developed a leading rice recombinant protein expression system, with its core product HY1001 approved for treating liver cirrhosis [2][3] - Xi'an Yicai specializes in the research, production, and sales of 12-inch silicon wafers, ranking first in mainland China and sixth globally in terms of monthly shipment and production capacity [3] Group 2: Performance of Existing Companies - The 32 existing companies in the Sci-Tech Growth Layer achieved a total revenue of 675.75 billion yuan in 2024, with 29 companies surpassing 100 million yuan in revenue [5][6] - The average annual compound growth rate of revenue for these companies reached 27.87%, outperforming the overall growth rate of the Sci-Tech Innovation Board [6] - In the first half of 2025, these companies reported a year-on-year revenue growth of 37.79% and a significant reduction in losses, with a total loss reduction of 71.23 billion yuan [6][7] Group 3: R&D Investment and Innovation - The existing companies collectively invested 30.6 billion yuan in R&D in 2024, with a median R&D investment-to-revenue ratio of 65.40%, leading the Sci-Tech Innovation Board [6][9] - Since the establishment of the Sci-Tech Board, 22 previously unprofitable companies have achieved profitability, with an average of four companies "delisting" from the unprofitable status each year [6][7] - The Sci-Tech Growth Layer has facilitated significant collaborations, such as the global strategic partnership between Baili Tianheng and Bristol-Myers Squibb, which involved an upfront payment of 800 million USD [8][9] Group 4: Future Outlook - The establishment of the Sci-Tech Growth Layer is expected to attract more technology companies, expanding the coverage of the Sci-Tech Innovation Board and providing a broader market space for quality tech enterprises [10] - The focus on high-level technological self-reliance and the development of new productivity will be key objectives during the 14th Five-Year Plan period, with the Sci-Tech Growth Layer playing a crucial role in this process [10]

Core Insights - In the period from January to October 2025, a total of 87 new companies were listed on the A-share market, representing an 8.75% increase compared to the same period last year, which had 80 new listings [1] - The total net fundraising amount for these 87 new listings reached 833.81 billion yuan, marking a significant 77.02% increase from 471.02 billion yuan in the same period last year [1] Underwriting Institutions Performance Ranking - A total of 29 underwriting institutions participated in the IPOs of these 87 new companies, with a total of 88 deals completed [2] - The top five underwriting institutions by number of deals are: - 1st: Guotai Junan with 11 deals - 2nd: CITIC Securities with 10 deals - 3rd: Huatai United with 8 deals - 4th: CITIC Jianzhong with 7 deals - 5th: China Merchants Securities with 5 deals [2][3] Law Firms Performance Ranking - In the same period, 28 law firms provided legal services for the IPOs of the 87 new companies [6] - The top five law firms by number of deals are: - 1st: Shanghai Jintiancheng with 13 deals - 2nd: Beijing Deheng and Beijing Zhonglun, both with 7 deals - 4th: Beijing Guofeng with 6 deals - 5th: Shanghai Tongli with 5 deals [6][7] Accounting Firms Performance Ranking - A total of 16 accounting firms provided auditing services for the 87 new listings [9] - The top five accounting firms by number of deals are: - 1st: Rongcheng with 20 deals - 2nd: Tianjian with 16 deals - 3rd: Lixin and Zhonghui, both with 11 deals - 5th: Ernst & Young Hua Ming, KPMG Huazhen, and Zhongshen Zhonghuan, each with 4 deals [9][10]

Market Performance - The Sci-Tech Innovation Board (STAR Market) index rose by 1.18%, closing at 1489.12 points, with a total trading volume of 4.52 billion shares and a turnover of 232.84 billion yuan [1] - Among the tradable stocks on the STAR Market, 296 stocks closed higher, with 10 stocks increasing by over 10% and 25 stocks rising between 5% and 10% [1] Trading Activity - The average turnover rate for the STAR Market was 2.37%, with 3 stocks having a turnover rate exceeding 20% and 14 stocks between 10% and 20% [1] - The highest turnover rate was recorded by C Yicai at 51.17%, with a closing price increase of 3.88% and a daily trading volume of 2.216 billion yuan [1] - C Heyuan, another new stock, saw a significant increase of 24.28% with a turnover rate of 50.96% and a trading volume of 2.171 billion yuan [1] Sector Analysis - In the high turnover stocks, the electronics sector had the most representation, with 32 stocks, followed by power equipment and computer sectors with 15 and 10 stocks, respectively [2] - Among the high turnover stocks, 49 stocks experienced net inflows of main funds, with Huahong Company, Aters, and Goodway receiving the highest net inflows of 449 million yuan, 418 million yuan, and 116 million yuan, respectively [2] Leverage and Financial Performance - A total of 64 stocks in the high turnover category received net purchases of leveraged funds, with notable increases in financing balances for Ju Chen Co., Huafeng Technology, and Western Superconducting, which saw increases of 462 million yuan, 343 million yuan, and 313 million yuan, respectively [3] - Among the high turnover stocks, 52 companies reported their Q3 earnings, with Zhongyou Technology, Shijia Photon, and Huafeng Technology showing significant net profit growth rates of 1074.35%, 727.74%, and 558.51%, respectively [3]

Core Insights - C Beite-U (688759) experienced a significant increase of 74.41% on its first trading day, with a turnover rate of 73.25% and a transaction volume of 1.107 billion yuan [2] - The stock's first-day margin trading saw a buy amount of 74.9658 million yuan, accounting for 6.77% of the total trading volume, with a latest margin balance of 60.908 million yuan, representing 4.23% of the circulating market value [2] - C Beite is a biopharmaceutical company focused on innovative drug development, targeting major diseases such as cancer, autoimmune diseases, and metabolic disorders, with a commitment to creating first-in-class drugs and addressing unmet clinical needs [2] Financial Performance - On its debut, C Beite-U recorded a net inflow of 413 million yuan from main funds, with large orders contributing 201 million yuan and extra-large orders adding 212 million yuan [2] - The first-day financing balance for C Beite-U was 60.908 million yuan, which is 4.23% of its circulating market value [2] Recent IPO Performance - The recent IPOs on the same day included C He Yuan-U (688765) with a 213.49% increase, C Yi Cai-U (688783) with a 198.72% increase, and Tai Kai Ying (920020) with a 188.53% increase, indicating a strong performance across multiple new listings [3]

Core Viewpoint - On October 28, Bibete experienced a significant stock price increase of 74.41%, with a trading volume of 1.107 billion yuan [1] Financing Summary - On the same day, Bibete recorded a financing purchase amount of 74.9658 million yuan, with a financing repayment of 14.0578 million yuan, resulting in a net financing purchase of 60.908 million yuan [1] - As of October 28, the total financing and securities lending balance for Bibete was 60.908 million yuan, which represents 4.23% of its market capitalization [1] Securities Lending Summary - On October 28, Bibete had no shares repaid or sold in the securities lending market, resulting in a selling amount of 0 yuan [1] - The securities lending balance and remaining shares were both recorded as 0 [1] Company Overview - Bibete Pharmaceutical Co., Ltd. is located in the Science City of Guangzhou, Guangdong Province, and was established on January 19, 2012, with its listing date on October 28, 2025 [1] - The company focuses on the independent research and development of innovative drugs [1] Financial Performance - For the period from January to September 2025, Bibete reported zero revenue and a net loss attributable to shareholders of 107 million yuan [1] - The number of shareholders increased to 48,000, reflecting a 95,870% increase compared to the previous period [1] - The average number of circulating shares per shareholder was 968, with no change from the previous period [1]

Core Points - The first three companies have been registered in the Sci-Tech Innovation Board's growth layer, marking a significant step in the capital market's support for technological innovation and the development of new productive forces [1][4] - The establishment of the Sci-Tech Growth Layer aims to enhance the inclusiveness and adaptability of the capital market, allowing unprofitable technology companies to access funding [5][7] - The introduction of the "1+6" policy framework has successfully facilitated the inclusion of unprofitable companies, with a total of 35 companies now listed in the growth layer [5][6] Group 1: Market Developments - The three newly listed companies, He Yuan Bio-U, Xi'an Yicai-U, and Bibete-U, represent the first batch of new registrations in the Sci-Tech Growth Layer, which aims to support high-tech industries [1][6] - The total number of companies listed on the Sci-Tech Innovation Board has reached 592, indicating a growing market [5] - The Shanghai Stock Exchange has completed necessary preparations for the listing of these companies within four months, demonstrating efficient regulatory processes [6] Group 2: Regulatory Insights - The China Securities Regulatory Commission (CSRC) emphasizes the importance of risk prevention, strong regulation, and promoting high-quality development in the capital market [4][12] - Future plans include enhancing the regulatory framework to better identify quality tech companies and support emerging sectors such as artificial intelligence and aerospace [12] - The CSRC aims to improve corporate governance and increase investor returns while fostering a market environment conducive to long-term capital investment [12] Group 3: Company Perspectives - Company leaders express gratitude for the new policies that have opened doors to capital markets, enabling faster technology commercialization and industrial capacity enhancement [6][11] - The focus for these companies will be on increasing R&D investment and delivering performance to reward investors [11] - The transition from a profit-oriented to a future-oriented evaluation approach reflects a shift in how companies are assessed for their potential in the capital market [9]